Literature DB >> 19364952

Phase 0 clinical trials: an answer to drug development stagnation?

Patricia M LoRusso.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19364952     DOI： 10.1200/JCO.2008.21.5798

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

Review 1.  Translational research in phase I trials.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

2.  CRISPR and the Rebirth of Synthetic Biology.

Authors:  Raheleh Heidari; David Martin Shaw; Bernice Simone Elger
Journal:  Sci Eng Ethics       Date:  2016-06-20       Impact factor: 3.525

3.  Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  S Percy Ivy; Lillian L Siu; Elizabeth Garrett-Mayer; Larry Rubinstein
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 4.  Ruthenium-based chemotherapeutics: are they ready for prime time?

Authors:  Emmanuel S Antonarakis; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-06       Impact factor: 3.333

Review 5.  A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug.

Authors:  Ashish A Gawai; Faisal Shaikh; Mangesh Gadekar; Nitin Deokar; Shivanand Kolhe; K R Biyani
Journal:  Turk J Pharm Sci       Date:  2017-04-15

Review 6.  The Valley of Death in anticancer drug development: a reassessment.

Authors:  David J Adams
Journal:  Trends Pharmacol Sci       Date:  2012-03-10       Impact factor: 14.819

Review 7.  Solving the lost in translation problem: improving the effectiveness of translational research.

Authors:  Ceren Ergorul; Leonard A Levin
Journal:  Curr Opin Pharmacol       Date:  2012-09-11       Impact factor: 5.547

Review 8.  Surgical oncology for gliomas: the state of the art.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Nat Rev Clin Oncol       Date:  2017-11-21       Impact factor: 66.675

Review 9.  The role of fMRI in drug development.

Authors:  Owen Carmichael; Adam J Schwarz; Christopher H Chatham; David Scott; Jessica A Turner; Jaymin Upadhyay; Alexandre Coimbra; James A Goodman; Richard Baumgartner; Brett A English; John W Apolzan; Preetham Shankapal; Keely R Hawkins
Journal:  Drug Discov Today       Date:  2017-11-15       Impact factor: 7.851

10.  Early-phase development of cancer prevention agents: challenges and opportunities.

Authors:  Marjorie Perloff; Vernon E Steele
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.